Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

SPANISH LUNG CANCER GROUP

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Early success of Roche drug vs lung cancer cited

February 3, 2011 - 12:00am

SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.

Science and Environment